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There is a growing interest in assessing dietary intake more accurately across different population groups, and
biomarkers have emerged as a complementary tool to replace traditional dietary assessment methods. The purpose
of this study was to conduct a systematic review of the literature available and evaluate the applicability and
validity of biomarkers of legume intake reported across various observational and intervention studies. A systematic
search in PubMed, Scopus, and ISI Web of Knowledge identified 44 studies which met the inclusion criteria for the
review. Results from observational studies focused on soy or soy-based foods and demonstrated positive
correlations between soy intake and urinary, plasma or serum isoflavonoid levels in different population groups.
Similarly, intervention studies demonstrated increased genistein and daidzein levels in urine and plasma following
soy intake. Both genistein and daidzein exhibited dose-response relationships. Other isoflavonoid levels such as O-
desmethylangolensin (O-DMA) and equol were also reported to increase following soy consumption. Using a
developed scoring system, genistein and daidzein can be considered as promising candidate markers for soy
consumption. Furthermore, genistein and daidzein also served as good estimates of soy intake as evidenced from
long-term exposure studies marking their status as validated biomarkers. On the contrary, only few studies
indicated proposed biomarkers for pulses intake, with pipecolic acid and S-methylcysteine reported as markers
reflecting dry bean consumption, unsaturated aliphatic, hydroxyl-dicarboxylic acid related to green beans intake
and trigonelline reported as marker of peas consumption. However, data regarding criteria such as specificity, dose-
response and time-response relationship, reliability, and feasibility to evaluate the validity of these markers is
lacking. In conclusion, despite many studies suggesting proposed biomarkers for soy, there is a lack of information
on markers of other different subtypes of legumes. Further discovery and validation studies are needed in order to
identify reliable biomarkers of legume intake.
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Legumes are fruits or seeds of a plant belonging to the
family Fabaceae and are a popular food source in the
traditional diets of many regions in the world.
Well-known legumes include peas, beans, lentils, lupins,
chickpeas, carob, soybeans, peanuts, and tamarind. They
provide proteins, complex carbohydrates, and soluble
and insoluble fibers. Legumes also contain a number of* Correspondence: lorraine.brennan@ucd.ie
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tates, protease, and chymotrypsin inhibitors as well as
micronutrients such as iron, copper, and manganese.
Consumption of legumes in general plays a role in the
prevention of cancer, cardiovascular disease, osteopor-
osis, and chronic degenerative diseases [1–3]. Further-
more, legumes have a low glycemic index, ranging from
10 to 40. In general, a serving of legumes (~ 100 g fresh
weight) provides 115 cal, 20 g of carbohydrates, 7–9 g of
fiber, 8 g of protein, and 1 g of fat [4].eptember/2018. Open Access This article is distributed under the terms of the
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part of the diet for the majority of Asian population, and
many studies have investigated their potential health pro-
moting effects. Soybeans and soy-based food products
contain uniquely high isoflavone content ~ 1–3 mg isofla-
vones/g protein, and one serving of traditional soy foods
provides ~ 25–40 mg isoflavones [5] as compared to other
commonly consumed plant foods. In fact, USDA Database
on the isoflavone content of the selected foods [6] has re-
ported very high total isoflavone content from soybean
and soy-based products as compared to other vegetables
and foods. Of the 114 commonly consumed vegetables of
Europe analyzed, the foods derived from soy contained
isoflavone concentration (500–1400 mg daidzein and ge-
nistein/kg) at least two orders of magnitude higher than
the next richest isoflavone food (raw mung beansprouts;
6 mg/kg) and several orders of magnitude higher concen-
tration than the non-leguminous sources [7]. Consump-
tion of an isoflavone rich soy diet has been linked to
improved health outcomes in a number of studies [5, 8–
10]. These health benefits may arise in part due to the
presence of various isoflavonoid components such as
daidzein, genistein, and glycitein which were characteristic
of soy possessing numerous biological functions [5]. These
isoflavonoids are found in conjugated form with either
glucose or 6″-O-malonyl- or 6″-O-acetylglucose in plants
[11]. Daidzein is further metabolized by intestinal gut bac-
teria to equol, O-desmethylangolensin (O-DMA), dihydro-
daidzein, and cis-4-OH-equol, while genistein is further
metabolized to dihydrogenistein and 6’-OH-O-DMA [12,
13]. The beneficial effects of soy seem to be related to the
combination of these compounds and not any one in par-
ticular. For example, daidzein and genistein were reported
to have a synergistic effect on inhibiting cell proliferation
and inducing apoptosis of prostate cancer cells [14]. In
addition, these compounds and equol were also proposed
to be antiestrogenic, antioxidative, and anticarcinogenic
and may protect against chronic diseases such as
hormone-dependent cancer, cardiovascular diseases, and
osteoporosis [15–19]. However, it is worth noting that a
few studies considering estrogenic effects of dietary soy
phytoestrogens have demonstrated that the isoflavones
promote growth of ER-positive breast cancer cells under
both in vitro as well as in vivo conditions [20–22]. With
respect to dietary pulses, a sub-group of legumes, dietary
intake has been associated with reduced chronic disease
risks for cardiovascular disease and cancer [23], as well as
with improvements in intermediate cardiovascular disease
risk factors, such as blood pressure, dyslipidemia, glycemic
control, and weight management [23–28]. Pulses also pro-
vide a valuable means of lowering the glycaemic-index
(GI) of the diet [28].
Due to the health benefits of legumes, there is a grow-
ing interest in assessing their dietary intake acrossdifferent populations. In order to achieve this to a high
standard, it is pertinent that we have more accurate and
reliable assessment tools to monitor their intake. The
classical approaches of data collection tools such as food
frequency questionnaires (FFQ), food dairies, and 24-h
dietary recalls are associated with a number of errors
[29–33]. Hence, there is a growing need for more object-
ive measures of intake, and biomarkers have emerged as
having great potential in this field. Such biomarkers
should be able to reflect the differences in dietary in-
takes across a number of population types [34].
The objective of this paper was to perform a system-
atic review of the literature and summarize the informa-
tion from observational and human intervention studies
on the biomarkers of legumes intake and also evaluate
the validity, reproducibility, and sensitivity of the pro-
posed markers that could potentially be useful indicators
of legume consumption.
Search methodology
The reviewing process made use of elements of Pre-
ferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement [35], which were
relevant for a search for literature on biomarkers. The
search methodology was also followed in accordance
with the guidelines for biomarkers of food intake reviews
(BFIRev) [36]. The search process included results until
16 February 2018. In brief, original research papers and
reviews were searched in three databases (PubMed, Sco-
pus, and ISI Web of Knowledge) using combinations of
the grouped search terms (legume OR bean OR pea)
AND (biomarker* OR marker* OR metabolite* OR bio-
kinetics OR biotransformation) AND (trial OR experi-
ment OR study OR intervention) AND (human* OR
men OR women OR patient* OR volunteer*) AND
(urine OR plasma OR serum OR blood OR excretion)
AND (intake OR meal OR diet OR ingestion OR con-
sumption OR eating OR drink*). The research was lim-
ited to papers in English language, while no restriction
was applied for the publication dates. The research pa-
pers identifying or using potential biomarkers of intake
for the foods were selected by one or more skilled re-
searcher from the list of retrieved references taking into
consideration inclusion criteria with literature focused
on intervention studies in which participants consume
known amount of specific foods and biological samples
collected and also population studies. The exclusion cri-
teria include literature reported with reference to effect
of physiology, drug metabolism, in vitro studies, food
analysis studies, animal studies, inappropriate study de-
signs, and non-specific articles to legumes food group
[36] as outlined in Fig. 1.
Considering the list of discriminating metabolites ob-
tained from the primary search, a secondary search was
Fig. 1 Flow diagram of the study selection
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biomarkers or precursors and to determine the apparent
specificity of the compound of interest. In this second
step, PubMed, Scopus, and Web of Science were used as
search platforms and the compounds checked for their
specificity were genistein, daidzein, dihydrogenistein,
dihydrodaidzein, enterodiol, enterolactone, matairesinol,
O-DMA, glycitein, kaempferol, dimethylamine, glutam-
ine, 3-methylhistidine, trigonelline, pipecolic acid, indo-
lepropionate, S-methylcysteine, and N-acetyl-ornithine
and their synonyms (Additional file 1: Table S1). For
each of these potential biomarkers identified, an add-
itional search was conducted using the following search
criteria (“the name and synonyms of the compound” OR
“the name and synonyms of any parent compound”)
AND (biomarker* OR marker* OR metabolite* OR bio-
kinetics OR biotransformation) AND (trial OR experi-
ment OR study OR intervention) AND (human* OR
men OR women OR patient* OR volunteer*) AND
(urine OR plasma OR serum OR blood OR excretion)
AND (intake OR meal OR diet OR ingestion OR con-
sumption OR eating OR drink*).
The validity of candidate biomarkers obtained from
the above search was further assessed through a
consensus-based procedure which evaluated a set of the
most important criteria for systematic evaluation of bio-
markers of food intake. The scoring scheme presented in
this review aimed to address criteria which includeplausibility, dose-response, time-response, robustness,
reliability, stability, analytical performance, and
inter-laboratory reproducibility (Table 2). A detailed ex-
planation of critical assessment of the criteria chosen for
biomarker validation was previously presented [37].
Results and discussion
The literature search performed identified a total of
2139 articles from the three databases, and a flow dia-
gram of the study selection is represented in Fig. 1. A
total of 1922 articles were obtained after removal of du-
plicates using Endnote X7.4. Of these, a total of 70 arti-
cles were selected after screening on the basis of title
and abstract. Exclusion criteria for the remaining 1852
articles included the following: effect on physiology, ef-
fect on drug metabolism, in vitro studies, food analysis,
and other articles related to antioxidant markers, dis-
ease/health markers, oxidative stress markers, articles
not relevant to intake biomarkers, and animal studies.
Full texts of the 70 papers were downloaded and
assessed further for exclusion/inclusion criteria. Exclu-
sion criteria at this stage included animal studies, in-
appropriate study design and articles not specific to
legume intake. In total, 44 articles were retained and
used for the development of the tables. Table 1 provides
a summary of the selected studies, including the candi-
date biomarkers for legumes/beans/peas intake identified
through this search process.
Table 1 List of reported putative legume biomarkers of intake
Dietary factor Subject Study design Number of
subjects
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Table 1 List of reported putative legume biomarkers of intake (Continued)
Dietary factor Subject Study design Number of
subjects
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Table 1 List of reported putative legume biomarkers of intake (Continued)
Dietary factor Subject Study design Number of
subjects
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Table 1 List of reported putative legume biomarkers of intake (Continued)
Dietary factor Subject Study design Number of
subjects
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metabolites as markers of soy intake
Examination of cross-sectional studies revealed that a
number of studies investigated the isoflavones and their
metabolites such as genistein, daidzein, glycitein, and
O-DMA in biological samples such as urine and blood
(serum and plasma) following the consumption of soy or
soy-based foods (Table 1).
A study conducted in 147 Singaporean Chinese with
spot urine samples demonstrated a statistically signifi-
cant, dose-dependent association between frequency of
overall soy intake and levels of urinary daidzein (p =
0.03) and sum of urinary daidzein, genistein, and glyci-
tein (P = 0.04) [38]. A dose-response relationship was
also observed between dietary soy consumption and
urinary excretion rates of daidzein, genistein, and glyci-
tein as well as with total isoflavones (p ≤ 0.05) in Chinese
women (n = 60) [39]. There were also positive correla-
tions established between urinary isoflavones excretion
and the amount of soy food, soy protein, and soy isofla-
vones intake (r = 0.50, p < 0.001, r = 0.53, p < 0.001 and
r = 0.54, p < 0.001, respectively). Similarly, another study
examining a Western population (n = 100) showed signifi-
cant correlations between soy protein intake from 24-h
recalls with daidzein (r = 0.72, (CI) 0.43, 0.96), genistein
(r = 0.67, (CI) 0.43, 0.91), and total isoflavones (r = 0.72,
(CI) 0.47, 0.98) [40]. Additionally, between FFQs andurinary excretion, the correlations were (r = 0.50, (CI)
0.32, 0.65), (r = 0.48 (CI) 0.29, 0.61) and (r = 0.50 (CI):
0.32, 0.64) for daidzein, genistein, and total isoflavones,
respectively [40]. Significant correlations were reported
between intake of soy foods through FFQ and 5-day diet
records, with urinary genistein (r = 0.40, p = 0.0001),
O-DMA (r = 0.37, p = 0.0002), daidzein (r = 0.34, p =
0.0007), and the sum of isoflavones (r = 0.39, p = 0.0001)
in US men and women (n = 98) [41]. In another US popu-
lation study, positive correlations were demonstrated
between self-reported soy intake and excretion of urinary
isoflavones (r = 0.52, p < 0.001 for dietary recall and r =
0.29, p < 0.01 for FFQ) [42]. In a US study (n = 451
women) [43], 24-h urine sample measures were shown to
be strongly correlated with overnight urine excretion for
daidzein (r = 0.84) and genistein (r = 0.93). The 24-h urine
sample measures were also correlated with soy food
questionnaire (SFQ) estimates of daidzein (r = 0.48) and
genistein (r = 0.54) intake [43]. A significant correlation
between isoflavones measured in an overnight urine and
soy protein intake estimated by self-reported intake
(dietary questionnaire) was also established in multieth-
nic population (n = 102), both in the previous 24 h
(r = 0.61, p < 0.0001) and in the past year (r = 0.32, p <
0.0012) [44]. Overall, significant correlations between soy
intake and urinary isoflavones excretion either in spot,
overnight, or 24-h urine samples were demonstrated
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to serve as dietary biomarkers.
While the above studies have focused on isoflavone
levels in urine, there was also evidence to support rela-
tionships in plasma and serum. A study of four groups
of 20 premenopausal British women (n = 80) demon-
strated significant correlations between dietary total soy
intake estimated by FFQ and food diaries with plasma
daidzein (r = 0.74–0.78, p < 0.001) and genistein (r =
0.73–0.78, p < 0.001) [45]. Similarly, significant correla-
tions were reported between genistein and daidzein
intakes as determined by soy FFQ with plasma concen-
trations (r = 0.53 and 0.45) respectively in a Western
population group (n = 77) [46]. Furthermore, similar
results were found in US postmenopausal women (n =
96) with correlations varying from 0.35 to 0.43 depend-
ing on the dietary intake instrument [47]. A statistically
significant (p = 0.002) threefold difference in mean
plasma levels of total isoflavones was observed between
women with high and low soy isoflavone intake levels as
determined from FFQ [48]. For the correlation between
serum isoflavones levels and soy intake, a significant lin-
ear trend (p < 0.01) was observed in serum isoflavones
(daidzein and genistein) concentrations across increasing
categories of soy food consumption estimated by FFQ in
Asian women (n = 1823) [49].
In summary, the cross-sectional studies demonstrated
that there were positive correlations between soy intake
with urinary, plasma, and serum isoflavones levels,
mainly daidzein and genistein, in different population
groups.
Acute and intervention studies reporting relationships
between soy intake and isoflavones and their metabolites
Soy isoflavones
The literature search identified a number of intervention
studies which focused on soy-based diets and isoflavo-
noid excretion in different population groups (Table 1).
Various acute studies have reported increased isoflavo-
noid concentrations in blood and urine following con-
sumption of soy-based foods (Table 1). To understand
the metabolic fate of dietary isoflavones in humans, a
study examined 24-h urines from 12 healthy Caucasian
male and female participants following 3 days of soy
challenge: the urinary isoflavone levels (genistein, daid-
zein, glycitein) peaked more than 3.8-fold and returned
to basal levels by day 4, while the major urinary metabo-
lites (O-DMA, equol, 6-hydroxy-O-DMA, dihydrodaid-
zein) demonstrated a more significant increase of over
5- to 40-fold and progressively fell over days 4 and 5
[50]. This marked variation among the major urinary
isoflavonoid metabolites may reflect variability in an in-
dividual’s ability to ferment isoflavones and the fat con-
tent of the diet [51]. A randomized controlled crossoverfeeding study demonstrated that the urinary excretion of
total isoflavones significantly increased with soy diet
(normal basal diet plus 100 g tofu and 45 g of soy pro-
tein isolate served per day) consumption (26.01 ±
2.30 μmol/day) as compared to the vegetable free
(0.75 μmol/day), carotenoid (0.51 μmol/day), and crucif-
erous vegetable diet (1.03 μmol/day) [52]. Overall, the
results from this study provide information on the utility
of urinary isoflavones as biomarkers of soy intake.
In another study, the urinary recovery of daidzein
levels were significantly higher than genistein (p < 0.001),
while the plasma concentrations of both isoflavones did
not differ significantly (p > 0.1) after single doses of 0.7,
1.3, and 2.0 mg isoflavones/kg body weight in soybean
milk [19]. Subsequently, a randomized, double-blind,
crossover study involving four 9-day soy protein bever-
age supplementation periods established a positive
dose-response between urinary isoflavones excretion and
soy intake (p = 0.0001) with no significant difference be-
tween equol excretors and non-excretors [53].
A study examining the repeated intake of consuming
soy protein powder of about 60 g/day in a controlled
intervention trial for over a period of 28 days demon-
strated that the plasma isoflavone levels markedly in-
creased on day 28 compared to day 0 with no change in
the control group on a casein supplement diet [54]. This
result was in agreement with other related studies,
which demonstrated an increase in isoflavonoid excre-
tion following a soy challenge [19, 50, 55, 56].
Glycitein is a soy isoflavonoid which constitutes 5 to
10% of the total isoflavones in the soy beans [57]. A few
cross-sectional studies have reported urinary excretion
of glycitein [38, 39, 44], but the excretion levels are
low compared to genistein and daidzein [58]. Max-
imum serum concentration for glycitein attained after
ingestion of aglycone and glucosidic forms of soy bev-
erage did not differ significantly (0.07–0.09 μmol/L),
and maximum urinary excretion was reported to be
~ 3 μmol [59]. Similarly, maximum glycitein plasma
concentration of ~ 200 ng/ml and maximum glycitein
urinary concentration of 11,000 ng/ml were reported
in a bioavailability study [60]. A large soy intervention
trial demonstrated a three- to fourfold increase in gly-
citein levels in plasma, overnight urine, and spot
urine was observed in the soy group compared to the
placebo. However, the magnitude of increase was
smaller compared to major soy isoflavones genistein
and daidzein [58].
Several studies have also reported differences in iso-
flavone excretion with respect to the type of soy
foods with most interest in the difference between
fermented and non-fermented sources. A study com-
paring the effects of fermented and non-fermented
soy product consumption demonstrated that the
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was higher (p < 0.002) when the subjects consumed
tempeh (fermented) compared to the soybean pieces
diet [56]. This suggests that the fermented products,
due to the hydrolysis of isoflavone glucosides to their
corresponding aglycones could have increased avail-
ability of the isoflavones. In contrast, urinary isoflavo-
noid excretion showed no significant difference upon
consumption of soymilk (non-fermented) compared to
miso soup (fermented) (p = 0.87) [61].
Similarly, a study comparing the effects of fermen-
ted and non-fermented soy product consumption
demonstrated that the plasma concentrations of ge-
nistein and daidzein were more than twice and five
times higher (p < 0.05) when subjects consumed fer-
mented soybean extract compared to non-fermented
soybean extract [62]. Similar results were reported
for total isoflavones with higher serum isoflavone
concentrations (~ 2 μmol/L) attained with fermented
soymilk ingestion compared to non-fermented soymilk
(~ 0.94 μmol/L) [59]. In contrast, reports following inges-
tion of commercial soy supplements have reported that
plasma isoflavone concentrations were higher following
ingestion of glucosidic forms compared to aglycone
forms [63, 64]. However, it should also be noted that
hydrolysis of isoflavone glycosides to their corresponding
aglycones did not seem to alter plasma concentrations in
some studies [65, 66].
Overall, the urinary excretion levels and plasma con-
centrations of soy isoflavones were reported to have vari-
able responses to the consumption of isoflavone
aglycone- and isoflavone glucoside-rich foods.
Pharmacokinetics of isoflavones
A number of studies investigated the pharmacokinetic
behavior of isoflavones following soy intake. In all stud-
ies, the shapes of the plasma appearance and disappear-
ance curves with respect to time exhibited biphasic
pattern as a result of enterohepatic circulation of the
compounds. Peak plasma concentration of isoflavones
following consumption of a soy-based meal was reported
for genistein at 8.42 ± 0.69 h (t1/2 = 5.7 ± 1.3 h) and daid-
zein at 7.42 ± 0.74 h (t1/2 = 4.7 ± 1.1 h) [67]. Similarly, ge-
nistein was reported as having a longer half-life (8.36 h)
compared to daidzein (5.79 h) following consumption of
60 g of kinako (baked soybean powder) [59]. Peak serum
concentrations of daidzein and genistein on average
were attained at 6.9 ± 0.7 h and 6.5 ± 1.0 h, respectively,
and their corresponding elimination half-lives were re-
ported as 8 and 10.1 h, respectively, following consump-
tion of 10, 20, or 40 g of soy nuts [68]. A curvilinear
relationship was established between bioavailability for
daidzein and genistein and the increased amount of soy
nuts intake. This suggests a decrease in serumconcentrations measured at increasing dosage levels.
The same study revealed that most of the excreted urin-
ary isoflavones were eliminated within the first 2 days
following consumption of soy nuts at different doses.
However, the urinary daidzein excretion decreased from
approximately 63 to 44%, while the urinary genistein ex-
cretion decreased from 25 to 15% upon increased
amount of soy nuts intake from 10 to 40 g. This
non-linear pharmacokinetic behavior over a dose range
reveals that optimum steady state isoflavone concentra-
tions can be achieved by multiple intakes of soy foods at
regular intervals of time than a single high dosage soy
product [68]. Similarly, a randomized two-phase cross-
over study reported peak plasma concentrations of daid-
zein and genistein on average attained at 6.08 h and
6.37 h, respectively, and their corresponding half-lives
were 7.17 h and 7.7 h, respectively [69]. Typically in all
of the studies, urinary recovery of genistein and daidzein
is complete within 24–36 h [70]. According to the evi-
dence obtained from the literature, both urine and
plasma can be considered suitable biofluids to measure
soy intake.
Chronic ingestion of soy isoflavones
A study in post-menopausal women who chronically
ingested the commercial soy-based preparation Prevas-
tein (46.19 g of total isoflavones expressed in the agly-
cone form per 100 g of preparation) for 30 and 60 days
demonstrated that the urinary and plasma concentra-
tions of genistein, daidzein, and equol remained constant
from day 15 until the end of experimental period [71].
The data suggest that chronic ingestion could lead to a
saturation point and optimum steady state biofluid con-
centrations can be achieved consistently with adequate
intake of soy foods or supplements. However, from a
biomarker view point, this may indicate a limitation for
estimation of high intakes [68, 71]. An intervention
study in young girls who consumed either one daily
serving of soymilk (8.5 oz) or soy nuts (1 oz) for 8-week
period demonstrated that urinary excretion of soy isofla-
vones increased by almost sixfold from baseline (23.3 to
142 nmol/mg creatinine). This finding was also reported
to be consistent with the 3-day food record which
showed a significant increase in isoflavone intake (5.4 to
32.6 mg/day) during the intervention period [72].
While there are many studies focused on concentra-
tion levels of isoflavones present in the biofluids follow-
ing consumption of a range of soy foods, these studies
have limited number of subjects and some of the studies
lack repeated collection of biofluids. A large randomized,
double-blind soy intervention trial with 350 postmeno-
pausal women for 3 years established high correlations
between isoflavone measurements of overnight urine,
spot urine, and plasma with Pearson correlations ranging
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significantly high isoflavone quantitative differences of
up to 3–19-fold between placebo and soy group and also
highly significant correlations between mean isoflavone
values and soy doses, but not in the placebo group. In
another two randomized soy trials conducted among
256 premenopausal women consuming high (~ 50 mg
isoflavones/day) and low (~ 10 mg isoflavones/day) soy
diets, urinary isoflavonoid excretion significantly corre-
lated to dietary isoflavone intake (r = 0.51, AUC = 0.85; p
< 0.0001) [73]. Overall, these studies provide further sup-
port for the use of isoflavones as biomarkers of dietary
soy intake.
Soybeans are consumed mainly as processed soy prod-
ucts such as tofu, milk, nuts, and protein isolate powder.
The influence of soy food matrix and the effect of indus-
trial processing has resulted in varied isoflavone contents
in soy-based products [74, 75]. The varied degree of pro-
cessing conditions has also influenced the metabolism,
pharmacokinetics, and bioavailability of soy isoflavones
[55, 64, 76, 77]. However, our review concentrated on
covering information on potential biomarkers obtained
from soy and soy-based food products rather than trying
to understand the influence of abovementioned condi-
tions on the bioavailability of biomarkers. Furthermore,
it should be noted that the biomarkers cannot distin-
guish between food and supplement sources.
Soy isoflavone metabolites
A number of soy isoflavone metabolites are found in the
circulation. The following section will highlight the key
isoflavone metabolites found in the literature review.
Equol is a major isoflavonoid estrogen metabolite pro-
duced from daidzein by gut microbiota and is produced
by ~ 30–40% of individuals after a soy challenge (named
“equol producers”) [70, 78]. A chronic soy exposure
study demonstrated that the urinary recovery of equol
increased by 3–100-fold (p < 0.05) over 4 weeks of daily
soy ingestion [79]. Similarly, a study examining the
prevalence of equol excretion in both male and female
individuals revealed that 35% of the participants among
the 60 were found to excrete equol following soy protein
beverage consumption after 3 days [80]. However, the
common isoflavones excreted after ingestion of
soy-based foods such as daidzein, genistein, and O-DMA
was similar between equol excretors and non-excretors
in both men and women [80]. A similar study demon-
strated an increase in equol production in older women,
while the total excretion of isoflavones remained the
same after a standardized dose of soy milk among three
generations of American-Japanese women [81]. The dif-
ferences in excretion could in part be attributed to dif-
ferential gut microbiota composition with age and
differential habitual dietary compositions [51, 82, 83].Equol production was studied over a period of 3 years,
and results indicated a high intraindividual variability
[84]. However, in other studies, equol production was
reported to be relatively stable over time [85, 86].
Such differences in equol production could be due to
dietary factors such as minor differences in intake of
micronutrients [87], but further research needs to be
done to consider other factors responsible for vari-
ation in equol production.
O-DMA is an isoflavonoid estrogen metabolite formed
when daidzein is metabolized to dihydrodaidzein by in-
testinal bacteria in the large intestine and further under-
goes ring cleavage [88]. Urinary excretion of O-DMA
was reported to be generally higher when subjects con-
sumed soy-based foods [50, 52, 56, 53, 89]. A random-
ized crossover study also demonstrated that O-DMA
appears in plasma after ~ 6–8 h post-consumption of
daidzein rich soy isoflavone preparation and also ob-
served almost a twofold increase after ingestion of pure
daidzein glucoside compared to the aglycone form. Urin-
ary excretion levels of O-DMA were also two times
higher following ingestion of the glucoside form com-
pared to aglycone form [63]. In a large soy intervention
trial, ~ 10-fold increase in O-DMA levels in plasma,
overnight urine, and spot urine was observed in the soy
group fed with soy beverage powder and soy bars com-
pared to the placebo fed with protein isolates and bars
with no isoflavone content [58]. A lower urinary isofla-
vone excretion value for O-DMA was reported in the
equol excretors probably due to conversion of daidzein
to equol [90].
Additionally, some studies have reported the urinary
dihydrogenistein and dihydrodaidzein (intermediate prod-
ucts of soy isoflavone metabolism) levels post-consumption
of soy-based foods [50, 91, 92]. Consumption of soy
compared to placebo resulted in ~ 4–7 fold higher
dihydrogenistein and dihydrodaidzein [58]. While these
soy isoflavone metabolites reveal interesting metabolic
information, it remains to be determined if they are
useful as biomarkers of soy intake.
Lignan phytoestrogens
A few studies have reported either low or no associ-
ation of lignans in biofluids to consumption of soy or
soy-based foods. The urinary excretion of lignans
enterodiol and enterolactone was reported to be low
after consumption of soy rich diet [93] and fermented
and unfermented soy products [56]. The enterolactone
levels were found to remain unaffected following a soy
challenge [50]. Furthermore, no differences in excre-
tion levels of lignans were found following soy-based
diet and basal diet consumption [52]. Subsequently,
the urinary excretion levels of lignans are high follow-
ing consumption of other sources of lignans such as
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compared to soy diet (0.84 ± 0.21 μmol/day) [52], and
hence, lignans cannot be considered as markers of soy
consumption.
Studies relating pulses intake to metabolites in biofluids
While most of the studies retrieved are focused on soy-
beans, there are a few studies which proposed metabo-
lites related to pulses intake. A randomized controlled
crossover human feeding study involving 46 middle-aged
men following consumption of a high dry bean-enriched
diet (250 g/day) for 4 weeks led to elevated serum levels
of pipecolic acid, S-methyl cysteine, N-acetylornithine,
trigonelline, and indole propionate [94]. Based on a fur-
ther study in which participants self-reported their dry
bean intake, only pipecolic acid and S-methyl cysteine
reflected dry bean consumption. Therefore, these two
metabolites were proposed as useful markers of dry
bean consumption [94]. In a different study, maximum
peak urinary excretion of kaempferol was observed after
2–8 h following consumption of cooked beans (Phaseolus
vulgaris L.) [95]. The average excretion was 6.1% and
5.4% of kaempferol dose for males and females respect-
ively. However, although the excretion profiles were
similar between subjects, a 6.72-fold inter-individual
variation in excretion concentrations was reported, which
was ascertained to variations in intestinal physiology [95].
A study examining urinary exposure markers of a wide
range of individual foods and food groups revealed that
the most probable food exposure marker for green beans
was an unsaturated aliphatic hydroxyl-dicarboxylic acid
[96]. An observational study aimed to characterize the
urinary metabolomic fingerprinting revealed glutamine,
dimethylamine, and 3-methylhistidine as candidate bio-
markers of pulse consumption [97]. A recent study iden-
tified trigonelline as urinary biomarker of pea intake
although reported to be non-specific marker of pea con-
sumption [98]. Notwithstanding the substantial research
performed on soy isoflavones, further research still needs
to be performed in order to identify potential biomarkers
of pulses and pulse-based foods in general.
Overall usefulness of the biomarkers
The assessment of data presented in Table 2 and the sec-
ondary search performed revealed that the compounds
genistein and daidzein are present in very high concen-
trations in soybeans and in moderate concentrations in
legume-based vegetables such as beansprouts, chickpeas,
lentils, fava bean, and roots of kudzu wine [7, 99].
They are also present in lower concentrations in other
fruits and vegetables such as potato, tomato, cabbage,
turnip, pumpkin, and asparagus [7]. Although there
are some reports of excretion of daidzein and genistein
and their precursors following consumption of redclover [100], the higher concentrations following soy
consumption make them highly specific markers of
soy consumption as evidenced in the published studies.
Moreover, genistein and daidzein were observed as
having a dose-dependent relationship with soy intake
in various observational studies [38, 39, 44, 46, 47].
Dose-response effects after a single bolus ingestion of
three different doses of soy isoflavones were also re-
ported [68]. The time-response relationship explaining
the elimination half-life of genistein and daidzein [64,
89] as well as kinetics of repeated intake [71] were
also highlighted in this review. Both genistein and
daidzein are also proven to be stable in urine and
plasma at − 20 °C for almost 3 months [101] and vari-
ous quantification methods using LCMS and GCMS
platforms for genistein and daidzein have been devel-
oped. The recovery %, limit of detection, and sensitivity
and specificity of genistein and daidzein were reported in
different analytical methods [102]. A multi-laboratory
validation study across seven different laboratories pro-
posed to determine and quantify the isoflavone content
in three soybean varieties showed a satisfactory interla-
boratory precision [103]. However, there are no reports
of individual isoflavones reported for interlaboratory
reproducibility. From a robustness point of view, while
the cross-sectional studies have demonstrated significant
associations with soy intake, a number of potential
confounding factors such as gut microbial populations,
intestinal transit time, and gender were identified. Fur-
thermore, data also exists which demonstrates that
plasma isoflavone concentrations were positively associ-
ated with age, fiber consumption, servings of fruits and
vegetables, and dietary supplements [98]. Consequently,
additional research efforts are needed to establish more
clearly the relationship between the biomarkers and ha-
bitual diet in larger population-based studies and after in-
take of complex meals in intervention studies with more
number of subjects.
Regarding isoflavone metabolites O-DMA, dihydro-
genistein, and dihydrodaidzein, the urinary excretion of
these compounds was weakly associated with soy food
intake [104], and furthermore, these metabolized isofla-
vones are also reported to be present in human urine
following red clover supplementation [105]. Taken to-
gether, this suggests the non-specificity of these metabo-
lites after soy intake.
From the studies examined, it is clear that genistein
and daidzein represent biomarkers of soy intake in dif-
ferent population groups. The influence of gender on
soy isoflavone excretion was reported with urinary genis-
tein recovery found to be higher after consumption of
soy-based foods in women, while no differences were
observed in males. Urinary daidzein recovery was not af-
fected by gender, but conversion to metabolite equol






1 2 3 4 5 6 7 8
Soy Genistein Urine Y Y Y N N Y Y U
Plasma/serum Y Y Y N N Y Y U
Dihydrogenistein Urine N U U N N U Y U
Plasma/serum N U U N N U Y U
Dihydrodaidzein Urine N U U N N U Y U
Plasma/serum N U Y N N U Y U
Enterodiol Urine N U U N N U Y U
Plasma/serum N U U N N U Y U
Enterolactone Urine N U U N N U Y U
Plasma/serum N U U N N U Y U
Matairesinol Urine N U U N N U Y U
Plasma/serum N U U N N U Y U
Daidzein Urine Y Y Y N N Y Y U
Plasma/serum Y Y Y N N Y Y U
Equol Urine N U Y N N U Y U
Plasma/serum N U Y N N U Y U
O-desmethylangolensin Urine N U U N N U Y U
Plasma/serum N U Y N N U Y U
Glycitein Urine Y U Y N N U Y U
Plasma/serum Y U Y N N U Y U
Pulses Kaempferol Urine N U Y U U U Y U
Dimethylamine Urine N U U U U U Y U
Glutamine Urine N U U U U U Y U
3-Methylhistidine Urine N U U U U Y Y U
Trigonelline Urine N Y U U U U N U
Plasma/serum N U U N U U Y U
Pipecolic acid Plasma/serum N U U Y U U Y U
Indolepropionate Plasma/serum U U U N U U U U
S-Methylcysteine Plasma/serum U U U Y U U U U
N-Acetyl-ornithine Plasma/serum U U U N U U U U
Possible answers are Y (yes), N (No), or U (unknown or uncertain)
Questions1. Is the marker compound plausible as a specific biomarker of food intake for the food or food group (chemical/biological plausibility)?2. Is there a
dose-response relationship at relevant intake levels of the targeted food (quantitative aspect)?3. Is the biomarker kinetics described adequately to make a wise
choice of sample type, frequency and time window (time-response)?4. Has the marker been shown to be robust after intake of complex meals reflecting dietary
habits of the targeted population (robustness)?5. Has the marker been shown to compare well with other markers or questionnaire data for the same food/food
group (reliability)?6. Is the marker chemically and biologically stable during biospecimen collection and storage, making measurements reliable and feasible
(stability)?7. Are analytical variability (CV%), accuracy, sensitivity and specificity known as adequate for at least one reported analytical method (analytical
performance)?8. Has the analysis been successfully reproduced in another laboratory (reproducibility)?
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isoflavones ingested and the dietary factors such as fiber
and carbohydrate [106]. Gender differences were also re-
ported with longer half-lives for plasma genistein and
daidzein in females as compared to males [79]. Further-
more, another factor that needs to be considered is the
effect of interindividual variation. Numerous studies have
shown considerable interindividual variation between
participants in the plasma and urinary concentrations of
isoflavones [19, 79, 107] and their metabolites especially
equol demonstrating multifold interindividual variation
[51, 80, 107]. It might be caused due to differences inabsorption and metabolism, differential gut microflora
composition, genetic variation in transporter genes, diet-
ary fat, carbohydrate, and fiber intake [41, 51, 108–110].
The lignan phytoestrogens enterodiol, enterolactone,
and matairesinol are widely distributed in many plant
classes, and their presence is more prevalent in whole
grains and fiber-containing plant foods (wheat, oats,
rye), oilseeds (flax seeds and sesame seeds), and various
other fruits and vegetables [70, 93, 111]. According to a
study conducted at USDA [112], high concentrations of lig-
nans were reported for flaxseeds (28,800–94,500 μg/100 g),
cereal grains (168.1–1084.1 μg/100 g), vegetables
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while lower levels were reported for soy (130–
1268 μg/100 g). The urinary excretion levels of lig-
nans as reported in the lignin phytoestrogen section
is high after consumption of sources other than
soy-based foods suggesting the limited role of soy as
a specific source of lignan phytoestrogens.
In parallel, an additional search was conducted for com-
pounds identified following pulse consumption to examine
the candidate biomarkers for specificity for pulses. The as-
sessment of data presented in Table 2 revealed that kaemp-
ferol is present in a wide range of edible plants such as tea,
broccoli, cabbage, kale, leek, tomato, strawberries, and
grapes [113]. Consequently, kaempferol has been detected
in biological samples after intake of other foods such as
fruits and vegetables [114, 115], onions [116, 117], tea [116,
118–121], other phenol-rich foods [122], and other
food sources [123–125]. Dimethylamine has been
proposed as a marker of fish consumption [126],
while 3-methylhistidine is a marker of chicken intake
[127]. On the other hand, trigonelline has also been
proposed as a biomarker of coffee with high concen-
trations reported after coffee intake [128–131]. Re-
garding pipecolic acid, it can be found in the urine
or serum after consumption of black soybean peptide
[132] and whole grain-enriched diet [133]; and in-
dole propionate was reported as marker of red meat
and eggs intake [134]. On the other hand, no rele-
vant papers were found to evaluate the specificity of
S-methylcysteine and N-acetyl-ornithine. Based on
the above information, the compounds detected in
the biofluids after consumption of beans are also
present in other food sources, and hence, none of
these compounds could be considered as specific
biomarkers of bean intake when evaluated alone.
Conclusions
Although many compounds have been suggested as
biomarkers for soy, pulses, and legumes in general, the
validation of these compounds against other markers for
the same food/food group needs to be performed. Over-
all, genistein and daidzein could potentially be consid-
ered as relevant markers of soy considering various
evidence from the literature such as dose-response
relationships and the suitability for detecting both acute
and habitual intake as evidenced from intervention and
cross-sectional studies. In addition, both genistein and
daidzein were proven as good estimates of soy intake as
evidenced from long-term exposure studies further
marking their status as validated biomarkers. Due to
the dearth of information on biomarkers of pulses,
further discovery and validation studies are needed in
this area in order to identify reliable biomarkers of
pulse intake.Additional file
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